analyst coverage | GenomeWeb

analyst coverage

The investment bank said Exact has the opportunity to book $4 billion to $5 billion in revenues a year from its colon cancer screening test Cologuard.

Based on a recent survey of 40 labs, the investment bank believes that labs will adopt the new NovaSeq instrument faster than previously anticipated. 

The investment bank Evercore ISI upgraded Illumina's stock in anticipation of sales of its NovaSeq sequencing instrument.

The company said the divestiture of its medical imaging business in the fourth quarter reduced revenues to below previous guidance.  

The bank rated companies like Thermo Fisher Scientific and Agilent at Buy, Illumina and PerkinElmer at Hold, and Myriad Genetics and Luminex at Sell.

The investment bank set a price target of $18.00 for shares of the molecular diagnostics company. 

The investment bank provided the updates as part of its 2017 outlook on the US life science tools and diagnostics markets.

Evercore said that Hologic's recent divestiture of its blood screening business limits near-term EPS growth; Piper, however, is looking forward to 2018.

The bank said that although it is forecasting a 17 percent stronger flu season this year, Quidel's influenza sales are only likely to rise 10 percent.

The investment bank also changed ratings for several omics companies, and revised price targets and estimates throughout its portfolio.

Pages

Harold Varmus, a former NIH director, says that proposed reductions to the agency's budget are worrisome.

The Genome 10K project is to sequence about 10,000 vertebrate genomes, including ones of endangered species, Digital Trends reports.

The new Coalition to Save NIH Funding aims to educate lawmakers and the public on the significance of biomedical research.

In PLOS this week: analysis of viral sequences from human blood samples, gut microbiomes of heart failure patients, and more.